For the second time this term, the U.S. Supreme Court has asked for the solicitor general’s views on a case involving Section 101 patent eligibility.

The high court issued a series of four controversial decisions on patent eligibility between 2010 and 2014, but has been silent since. The decisions have led to the rejection of thousands of patents, mostly in the software area but quite a few in the biopharma area as well.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]